Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide
博士 === 國防醫學院 === 生命科學研究所 === 102 === Dendritic cells (DCs) can process and present extracellular antigens on MHC class I molecules to activate cytotoxic T lymphocyte (CTL) responses through an important mechanism, antigen cross-presentation. However, toll-like receptor (TLR)-mediated cross-presentat...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Language: | en_US |
Published: |
2014
|
Online Access: | http://ndltd.ncl.edu.tw/handle/02005787959422829416 |
id |
ndltd-TW-102NDMC0105039 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-TW-102NDMC01050392015-10-13T23:49:48Z http://ndltd.ncl.edu.tw/handle/02005787959422829416 Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide 脂質化胜肽抗癌應用與抗原呈獻分子機制之探討 Kuan-Yin Shen 沈冠印 博士 國防醫學院 生命科學研究所 102 Dendritic cells (DCs) can process and present extracellular antigens on MHC class I molecules to activate cytotoxic T lymphocyte (CTL) responses through an important mechanism, antigen cross-presentation. However, toll-like receptor (TLR)-mediated cross-presentation of extracellular antigens by DCs remains unclear. In this study, models of synthetic di-palmitoylated peptides (Pam2IDG and Pam2EQL) explored the mechanisms of TLR2-mediated cross-presentation. We observed that TLR2 facilitated the internalization of di-palmitoylated peptides by bone marrow-derived DCs (BMDCs) via clathrin-mediated endocytosis. The immunization of di-palmitoylated peptide-pulsed BMDCs induced tumor regression through TLR2 signaling. These findings indicated that exogenous TLR2 agonist-conjugated peptide could be cross-presented to CTL. We further identified di-palmitoylated peptides-induced antigen-specific CTL responses was transporter associated with antigen processing (TAP) independent. In addition, endosomal acidification inhibitor (chloroquine) or a lysosomal degradation inhibitor (Z-FL-COCHO) could block the presentation of di-palmitoylated peptides by MHC class I molecules. The endocytosed di-palmitoylated peptide was delivered rapidly from early endosome antigen-1 (EEA1)-positive endosomes to RAS-related GTP-binding protein 7 (Rab7)-associated late endosomes compared with their non-lipidated counterparts. Furthermore, we found that the Rab7 expression co-related was up-regulated by di-palmitoylated peptide was via the TLR2/MyD88 pathway. Therefore, di-palmitoylated peptide could be cross-presented efficiently via vacuolar pathway to enhance CTL responses though TLR2 signaling. In conclusion, our data suggest that TLR2-mediated cross-presentation is through the upregulation of Rab7 and a vacuolar pathway to prime CTL responses. Shih-Jen Liu 劉士任 2014 學位論文 ; thesis 69 en_US |
collection |
NDLTD |
language |
en_US |
format |
Others
|
sources |
NDLTD |
description |
博士 === 國防醫學院 === 生命科學研究所 === 102 === Dendritic cells (DCs) can process and present extracellular antigens on MHC class I molecules to activate cytotoxic T lymphocyte (CTL) responses through an important mechanism, antigen cross-presentation. However, toll-like receptor (TLR)-mediated cross-presentation of extracellular antigens by DCs remains unclear. In this study, models of synthetic di-palmitoylated peptides (Pam2IDG and Pam2EQL) explored the mechanisms of TLR2-mediated cross-presentation. We observed that TLR2 facilitated the internalization of di-palmitoylated peptides by bone marrow-derived DCs (BMDCs) via clathrin-mediated endocytosis. The immunization of di-palmitoylated peptide-pulsed BMDCs induced tumor regression through TLR2 signaling. These findings indicated that exogenous TLR2 agonist-conjugated peptide could be cross-presented to CTL. We further identified di-palmitoylated peptides-induced antigen-specific CTL responses was transporter associated with antigen processing (TAP) independent. In addition, endosomal acidification inhibitor (chloroquine) or a lysosomal degradation inhibitor (Z-FL-COCHO) could block the presentation of di-palmitoylated peptides by MHC class I molecules. The endocytosed di-palmitoylated peptide was delivered rapidly from early endosome antigen-1 (EEA1)-positive endosomes to RAS-related GTP-binding protein 7 (Rab7)-associated late endosomes compared with their non-lipidated counterparts. Furthermore, we found that the Rab7 expression co-related was up-regulated by di-palmitoylated peptide was via the TLR2/MyD88 pathway. Therefore, di-palmitoylated peptide could be cross-presented efficiently via vacuolar pathway to enhance CTL responses though TLR2 signaling. In conclusion, our data suggest that TLR2-mediated cross-presentation is through the upregulation of Rab7 and a vacuolar pathway to prime CTL responses.
|
author2 |
Shih-Jen Liu |
author_facet |
Shih-Jen Liu Kuan-Yin Shen 沈冠印 |
author |
Kuan-Yin Shen 沈冠印 |
spellingShingle |
Kuan-Yin Shen 沈冠印 Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide |
author_sort |
Kuan-Yin Shen |
title |
Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide |
title_short |
Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide |
title_full |
Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide |
title_fullStr |
Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide |
title_full_unstemmed |
Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide |
title_sort |
anti-tumor effects and antigen presentation mechanisms of toll-like receptor 2 (tlr2) agonist-conjugated peptide |
publishDate |
2014 |
url |
http://ndltd.ncl.edu.tw/handle/02005787959422829416 |
work_keys_str_mv |
AT kuanyinshen antitumoreffectsandantigenpresentationmechanismsoftolllikereceptor2tlr2agonistconjugatedpeptide AT chénguānyìn antitumoreffectsandantigenpresentationmechanismsoftolllikereceptor2tlr2agonistconjugatedpeptide AT kuanyinshen zhīzhìhuàshèngtàikàngáiyīngyòngyǔkàngyuánchéngxiànfēnzijīzhìzhītàntǎo AT chénguānyìn zhīzhìhuàshèngtàikàngáiyīngyòngyǔkàngyuánchéngxiànfēnzijīzhìzhītàntǎo |
_version_ |
1718087278565261312 |